Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
1.570
-0.130 (-7.65%)
At close: Jun 27, 2025, 4:00 PM
1.600
+0.030 (1.90%)
After-hours: Jun 27, 2025, 7:45 PM EDT
Cabaletta Bio Employees
As of December 31, 2024, Cabaletta Bio had 164 total employees, including 161 full-time and 3 part-time employees. The number of employees increased by 61 or 59.22% compared to the previous year.
Employees
164
Change (1Y)
61
Growth (1Y)
59.22%
Revenue / Employee
n/a
Profits / Employee
-$772,927
Market Cap
83.76M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CABA News
- 17 days ago - Cabaletta Bio Announces Pricing of Public Offering of Securities - GlobeNewsWire
- 17 days ago - Cabaletta Bio: Sector Headwinds And Funding Issues - Seeking Alpha
- 17 days ago - Cabaletta Bio Announces Proposed Public Offering of Securities - GlobeNewsWire
- 17 days ago - Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - GlobeNewsWire
- 4 weeks ago - Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts - GlobeNewsWire
- 3 months ago - Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire